Loading...

BioSenic S.A.

BIOS.BR•EURONEXT
Healthcare
Biotechnology
€0.002
€-0.00(-4.17%)

BioSenic S.A. (BIOS.BR) Stock Overview

Explore BioSenic S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.9/100

Key Financials

Market Cap1.5M
P/E Ratio-0.06
EPS (TTM)$-0.04
ROE0.34%
Fundamental Analysis

AI Price Forecasts

1 Week$0.00
1 Month$0.00
3 Months$0.00
1 Year Target$0.00

BIOS.BR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioSenic S.A. (BIOS.BR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 51.71, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.06 and a market capitalization of 1.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

51.71RSI (14)
0.00MACD
40.49ADX
Stats data is not available for BIOS.BRStats details for BIOS.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for BIOS.BRAnalyst Recommendations details for BIOS.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.

CEO

Alexia Rieger

Employees

12

Headquarters

Building H (box 24), Mont-Saint-Guibert

Founded

2015

Frequently Asked Questions

;